J Neuropsychiatry Clin Neurosci 11:271-273, May 1999
© 1999 American Psychiatric Press, Inc.
Clinical and Research Reports |
Moclobemide Treatment in Multiple Sclerosis Patients With Comorbid Depression
An Open-Label Safety Trial
Yoram Barak, M.D.,
Erel Ur, LL.B. and
Anat Achiron, M.D., Ph.D.
Received February 20, 1998; revised April 16, 1998; accepted August 20, 1998. From the Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Abarbanel Mental Health Center, Bat-Yam, Israel. Address correspondence Dr. Barak, Abarbanel Mental Health Center, 15, Keren-Kayemet Blvd., Bat-Yam, Israel.
ABSTRACT
Depression is common in multiple sclerosis (MS) patients, but tricyclic compounds are not well tolerated and newer antidepressants have not been studied. Effects of 150–400 mg/day of moclobemide, a reversible monoamine oxidase A inhibitor, were studied in a 3-month open design in 10 MS patients with DSM-IV-diagnosed depression. Nine patients reached complete remission. No adverse effects were noted. Four patients reported side effects including nausea and insomnia. The authors conclude that moclobemide is a well tolerated and efficient treatment for depression comorbid with MS.
Key Words: Multiple Sclerosis • Depression • Moclobemide
This article has been cited by other articles:
|
|
|
|
 
A. Feinstein
Multiple sclerosis, disease modifying treatments and depression: a critical methodological review
Multiple Sclerosis,
October 1, 2000;
6(5):
343 - 348.
[Abstract]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1999
American Neuropsychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
